Breathe Well Live Well
|
Dynavax Technologies to commence Phase I asthma studies
Equities.com Comtex News Network. Nov 02, 2012 (Datamonitor via COMTEX) — Dynavax Technologies Corporation, a biopharmaceutical company, has announced that it will advance AZD1419, a second-generation TLR-9 agonist for asthma, into Phase I clinical studies. |
View full post on asthma – Google News
|
GlaxoSmithKline initiates Phase III refractory asthma program
Equities.com The Phase III program includes two key studies: MEA115588: A 32-week multicenter, randomized, double-blind, double-dummy, placebo-controlled study in patients with severe uncontrolled refractory asthma. The primary endpoint of the study is to evaluate … Glaxo Starting Late-Stage Study of Asthma Drug GlaxoSmithKline starts final-stage tests on severe asthma drug GSK takes severe asthma antibody into phase III |
View full post on asthma – Google News
|
Rigel commences two Phase II allergic asthma and DLE studies
Equities.com Approximately 270 adults with allergic asthma will be randomized into the three arms of this Phase II clinical study of R343, called SITAR, or SYK Inhibition for Treatment of Asthma with R343, for eight weeks of treatment with either of two different … |
View full post on asthma – Google News
 MedPage Today |
Israel : TEVA bags approval from FDA to market generic asthma treatment …
Equities.com US Food and Drug Administration (FDA) have given its approval to Teva Pharmaceutical Industries Ltd. for generic versions of asthma and allergies treatment Singulair in adults and children. Made by Merck & Co., brand Singulair has $5 billion in annual … New generic Singulair could save asthma sufferers big bucks Generic Singulair Approved FDA approves generic versions of asthma, allergy drug |
View full post on asthma – Google News
|
SkyePharma's Asthma Drug Finally Approved in Europe
Equities.com LONDON – The asthma treatment Flutiform finally won the seal of the European Commission last week, more than 12 years after SkyePharma plc set its sights on what it thought would be the relatively straightforward development of a combination product … Small caps: Drug OK lifts SkyePharma |
View full post on asthma – Google News